烷化剂诱导的甲状腺髓样癌高肿瘤突变负荷及免疫检查点抑制剂应答:两例病例报告
两例酪氨酸激酶抑制剂治疗后进展的转移性甲状腺髓样癌患者,接受达卡巴嗪或替莫唑胺等烷化剂治疗后出现高肿瘤突变负荷及烷化剂诱变特征(单碱基置换11)。两例接受免疫检查点抑制剂后均获部分形态学缓解和临床获益,无进展生存期分别为6个月和9个月。作者建议高突变表型可能由烷化剂诱导,序贯免疫治疗值得进一步探索。
要点
- 转移性甲状腺髓样癌患者经烷化剂治疗后可出现高肿瘤突变负荷及单碱基置换11突变特征。
- 两例高突变表型患者接受免疫检查点抑制剂后获部分形态学缓解,无进展生存期分别为6个月和9个月。
- 作者建议序贯免疫治疗作为肿瘤突变负荷升高的甲状腺髓样癌患者的治疗选择值得进一步探索。
核心结论
- 基于所描述的观察,作者建议甲状腺髓样癌烷化剂治疗后可能诱导高突变表型,序贯免疫治疗作为肿瘤突变负荷升高的甲状腺髓样癌患者的治疗选择应进一步探索。
研究设计与样本
- 两例病例报告,描述两例转移性甲状腺髓样癌患者在烷化剂治疗后出现高突变表型并接受免疫检查点抑制剂治疗。
主要发现
- 两例转移性甲状腺髓样癌患者在酪氨酸激酶抑制剂治疗后进展,接受达卡巴嗪或替莫唑胺等烷化剂治疗后出现高肿瘤突变负荷及烷化剂诱变特征(单碱基置换11)。
- 两例患者接受免疫检查点抑制剂后均获部分形态学缓解和临床获益,无进展生存期分别为6个月和9个月。
临床怎么用
- 作者建议序贯免疫治疗作为肿瘤突变负荷升高的甲状腺髓样癌患者的治疗选择应进一步探索。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Patients with metastatic medullary thyroid cancer (MTC) who progressed under tyrosine kinase inhibitors can benefit from an alkylating agent such as dacarbazine or temozolomide. Patient Findings: We describe two patients with metastatic MTC who developed a hypermutant phenotype after alkylating agent treatment. This phenotype was characterized by a high tumor mutational burden (TMB) and a mutational signature indicative of alkylating agent mutagenesis (single-base substitution 11). Both patients received immune checkpoint inhibitors, with partial morphological responses, clinical benefit, and progression-free survival of 6 and 9 months, respectively. Summary and Conclusions: Based on the described observations, we suggest that a hypermutant phenotype may be induced after alkylating agent treatment for MTC and the sequential use of immunotherapy should be further explored as a treatment option for MTC patients with increased TMB.
引用
- Moog S, Lamartina L, Bani MA, et al. Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports. Thyroid. 2023. PMID: 37698883. doi:10.1089/thy.2023.0144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。